Settlement Agreement under which the company agreed to payments and separation benefits in connection with Mr. Race's resignation, including a one-time severance payment.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Remy Luthringer
Also a director
Chief Executive Officer and Executive Chairman of the Board of Directors
|
65 | Not stated | Not stated | $9,354,184 | |
|
Frederick Ahlholm
Chief Financial Officer
|
60 | Not stated | 2014 | $2,469,211 | |
|
Joseph H. Reilly
Chief Operating Officer
Title from the Form 3 dated Aug 10, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
James O’Connor
Chief Business Officer and General Counsel
|
52 |
Since 2026
this year
|
Not stated | Not reported | |
|
Anthony Aliquo
Chief Accounting Officer
Title from the Form 8-K dated Aug 10, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Settlement Agreement under which the company agreed to payments and separation benefits in connection with Mr. Race's resignation, including a one-time severance payment.
Consultancy Agreement under which Mr. Race will provide consulting services to the company at an hourly fee.
Consulting Agreement under which Dr. Kaul provides clinical trial and related services at an hourly rate.
Option grant to Dr. Kaul, a consultant option for 0.7% of the Share Total with staged vesting, plus top-up options.
Participation in the 2025 Private Placement of Series A Preferred Stock and warrants.
Support Agreements under which these stockholders agreed to vote their shares for specified proposals in connection with the 2025 Private Placement.
Purchase of 1,425,000 shares of Common Stock and pre-funded warrants for 575,575 shares in the 2023 Private Placement.
Right to designate a board observer until a Change of Control or until its holdings fall below 10% of Common Stock; observer designated August 29, 2023.
Loading...